news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

our reporter xia gaoqin (chinatimes.net.cn) reports from nanjing

spice product manufacturer green biotech co., ltd. (hereinafter referred to as "green biotech") failed in its gem ipo.

recently, the shenzhen stock exchange updated the latest progress of green bio's ipo review on its website for public information disclosure. because green bio and its sponsor withdrew their application for listing, the shenzhen stock exchange decided to terminate its listing review in accordance with regulations. it is worth noting that this is the second time that green bio has failed to pass the gem ipo.

in 2021, green biotech withdrew its gem ipo application after being selected for on-site inspection. the company said that due to declining performance and omissions in information disclosure, the sponsor insisted on withdrawing the application. according to the latest prospectus data, green biotech has escaped the threat of declining performance, and the company's performance has achieved stable growth from 2021 to 2023. however, a reporter from the china times noted that during the reporting period, green biotech's cash flow was in crisis, and monetary funds could no longer cover short-term debts. in this application for listing, green biotech plans to raise 375 million yuan, which will be mainly used to supplement cash flow in addition to expanding production capacity.

now green bio has once again chosen to withdraw its application for listing. the reporter called green bio many times regarding the relevant situation of this ipo and the company's subsequent arrangements, but received no response.